Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have received a consensus rating of “Hold” from the eight ratings firms that are currently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $25.75.

ATRA has been the subject of several analyst reports. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. ValuEngine raised shares of Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Jefferies Group LLC reissued a “buy” rating and issued a $30.00 price objective on shares of Atara Biotherapeutics in a research note on Thursday, August 31st. Canaccord Genuity set a $47.00 price objective on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a research note on Monday, August 7th. Finally, BidaskClub downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd.

ILLEGAL ACTIVITY WARNING: “Atara Biotherapeutics, Inc. (ATRA) Given Average Rating of “Hold” by Brokerages” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/09/atara-biotherapeutics-inc-atra-given-average-rating-of-hold-by-brokerages.html.

Shares of Atara Biotherapeutics (NASDAQ:ATRA) traded down 1.66% during midday trading on Friday, reaching $14.80. The company’s stock had a trading volume of 70,105 shares. The company’s market cap is $452.27 million. Atara Biotherapeutics has a 12 month low of $11.80 and a 12 month high of $23.00. The company’s 50-day moving average price is $14.78 and its 200-day moving average price is $15.86.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by $0.05. On average, equities analysts anticipate that Atara Biotherapeutics will post ($3.89) EPS for the current fiscal year.

In other news, CEO Isaac E. Ciechanover sold 2,800 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $16.94, for a total transaction of $47,432.00. Following the transaction, the chief executive officer now directly owns 731,859 shares of the company’s stock, valued at $12,397,691.46. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Christopher Haqq sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $12.65, for a total transaction of $75,900.00. Following the transaction, the executive vice president now directly owns 368,080 shares in the company, valued at $4,656,212. The disclosure for this sale can be found here. In the last three months, insiders sold 49,509 shares of company stock valued at $726,242. 16.10% of the stock is owned by insiders.

Large investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Atara Biotherapeutics during the first quarter worth approximately $132,000. Voya Investment Management LLC increased its position in shares of Atara Biotherapeutics by 16.2% during the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 1,651 shares during the period. DekaBank Deutsche Girozentrale purchased a new position in shares of Atara Biotherapeutics during the first quarter worth approximately $185,000. State of Wisconsin Investment Board purchased a new position in shares of Atara Biotherapeutics during the second quarter worth approximately $252,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Atara Biotherapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after acquiring an additional 1,369 shares during the period. 82.95% of the stock is currently owned by institutional investors and hedge funds.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.